MDX2001 is a tetraspecific T cell engager that binds CD3 and CD28 on T cells and binds the tumor associated antigens cMet and Trop2. We developed a quantitative systems pharmacology (QSP) model to address the complexities in translating a high valency T cell engager from preclinical data to the clinic, and inform the first-in-human dosing of MDX2001 for solid tumors.

This work features a collaboration between ModeX Therapeutics and Certara.